Discovery of Scrophularia nodosa harpagoside synthase, a novel BAHD cinnamoyltransferase, bridges a key gap in the iridoid biosynthetic pathway

This study identifies and characterizes harpagoside synthase, a novel BAHD cinnamoyltransferase in *Scrophularia nodosa* with a unique VYPWG motif, thereby completing the biosynthetic pathway for the high-value anti-inflammatory compound harpagoside and offering a sustainable alternative to the overexploited *Harpagophytum procumbens*.

The Gist

Imagine you have a very special, expensive, and powerful medicine called Harpagoside. It's a natural painkiller and anti-inflammatory agent, famously found in a desert plant called Harpagophytum procumbens (or "Devil's Claw").

Here's the problem: To get this medicine, people have to dig up the entire plant and kill it. The plant grows very slowly in the desert, and because everyone wants the medicine, the plant is running out of space and time. It's like trying to get a rare diamond by smashing the only mine that has it.

Scientists wanted to find a better way. They asked: "Is there another plant that makes this same medicine, but one that is easy to grow and doesn't need to be destroyed to harvest?"

They found a candidate: Scrophularia nodosa, a common figwort plant found in Western Europe. It's like a "cousin" to the desert plant, and it happens to be packed with Harpagoside in its leaves. But there was a catch: Nobody knew exactly how this plant built the medicine. It was like knowing a factory produces a car, but having no idea how the engine, wheels, or steering wheel were assembled.

The Detective Work: Finding the "Assembly Line"

The scientists decided to become molecular detectives. They wanted to map out the entire "assembly line" inside the plant that builds Harpagoside, step-by-step.

1. Reading the Blueprint (Genomics):
   First, they took a snapshot of the plant's entire instruction manual (its DNA). They used high-tech sequencing to read every single letter of the plant's genetic code. This gave them a list of every possible "worker" (enzyme) the plant could have.

2. The Early Steps (The Foundation):
   They knew the first few steps of building the molecule were similar in many plants. They found the genes for these early steps and tested them in a "test tube" plant (tobacco leaves). It worked! They successfully built the basic "chassis" of the molecule.

3. The Missing Link (The Final Touch):
   The hardest part was the very last step. To turn the basic molecule into the final medicine (Harpagoside), the plant needs to attach a specific "decoration" (a cinnamoyl group) to it. This is like putting the final, custom paint job on a car.

   The scientists knew a specific family of enzymes (called BAHD) usually does this kind of painting. But there were hundreds of them in the plant's genome. Which one was the right painter?

The "VYPWG" Clue

The scientists looked closely at the "uniforms" (protein structures) of these BAHD enzymes. Most of them had a standard logo on their chest: DFGWG.

But, they found a special group of enzymes in the Scrophularia plant that wore a different, rare logo: VYPWG. It was like finding a secret club of painters who all wore a unique badge.

They narrowed it down to one specific gene, named Sno.1336. They guessed this was the "Master Painter" (Harpagoside Synthase).

The Proof: Bringing it to Life

To prove their guess was right, they took the gene for Sno.1336 and put it into yeast cells (tiny biological factories). They fed the yeast the raw materials and the "paint."

It worked! The yeast started producing Harpagoside. They confirmed it by checking the chemical fingerprint, which matched the real medicine perfectly.

Why This Matters

This discovery is a game-changer for three reasons:

• Sustainability: Instead of destroying rare desert plants, we can now grow the common figwort plant in greenhouses. It's like switching from mining diamonds to growing synthetic ones in a lab.
• The "Secret Sauce": They found a new type of enzyme (the one with the VYPWG logo) that is very picky. It only accepts specific types of "paint" (cinnamoyl-CoA) and ignores others. This helps scientists understand how nature creates such diverse and complex medicines.
• Future Medicine: Now that we know the exact recipe and the workers needed, we can engineer plants or yeast to mass-produce Harpagoside and other similar medicines cheaply and ethically.

In short: The scientists found a new, sustainable factory for a life-saving medicine, figured out the exact blueprint for how it's built, and identified the specific worker responsible for the final, crucial step. They turned a mystery into a manufacturing manual.

Technical Summary

1. Problem Statement

• High-Value Compound Scarcity: Harpagoside is a potent anti-inflammatory and analgesic iridoid glycoside. Its primary natural source is Harpagophytum procumbens (Devil's Claw), a desert plant from Southern Africa.
• Sustainability Issues: H. procumbens is threatened by overexploitation due to destructive root harvesting and slow growth. Current cultivation and in vitro methods yield low harpagoside concentrations.
• Biosynthetic Knowledge Gap: While the "early" steps of the iridoid pathway (leading to nepetalactol) are well-characterized, the specific enzymes responsible for the "late" steps leading to harpagoside—particularly the final cinnamoylation of harpagide—remain unidentified. No cinnamoyl-specific transferase had been characterized in plants prior to this study.

2. Methodology

The authors employed a multi-omics and functional genomics approach using Scrophularia nodosa (a European figwort) as a new model organism, which accumulates high levels of harpagoside in its leaves.

• Genomic Resources:
  • Generated a high-quality de novo genome assembly (608.3 Mb, 18 pseudochromosomes) using Oxford Nanopore long-read sequencing and Illumina short reads.
  • Performed transcriptomic profiling (RNA-seq) across seven different plant tissues (roots, stems, leaves, buds, flowers) to correlate gene expression with metabolite accumulation.
• Pathway Reconstruction (Early Steps):
  • Identified homologs of early iridoid pathway enzymes (GES, G8O, 8HGO, IO, ISY, ICYC, e7DLGT) via homology search.
  • Validated the early pathway functionally by transient co-expression of candidate genes in Nicotiana benthamiana, confirming the production of 8-epi-deoxyloganic acid.
• Candidate Gene Discovery (Late Steps):
  • Focused on the BAHD acyltransferase family, known for acylating specialized metabolites.
  • Conducted phylogenetic analysis of the S. nodosa BAHD family, identifying a specific expansion in Clade 6i, specifically within Subclade 6i branches 2 and 3 (Lamiales/Scrophulariaceae specific).
  • Identified a unique VYPWG motif in these branches, replacing the canonical BAHD DFGWG motif.
  • Used Pearson correlation analysis to match BAHD gene expression profiles with harpagoside accumulation in different tissues.
• Functional Validation:
  • Selected the top candidate gene, Sno.1336, for recombinant expression in Komagataella phaffii (Pichia pastoris).
  • Purified the protein and performed in vitro enzymatic assays using various iridoid acceptors (harpagide, ajugol, etc.) and acyl-CoA donors (cinnamoyl-CoA, coumaroyl-CoA, etc.).
  • Analyzed products using LC-MS/MS and HPLC-UV.

3. Key Contributions

• First Cinnamoyltransferase Characterization: The study identifies and characterizes the first plant enzyme capable of transferring a cinnamoyl moiety to an iridoid scaffold.
• Discovery of Harpagoside Synthase (SnHS): The enzyme Sno.1336 (named SnHS) was confirmed to catalyze the final step of harpagoside biosynthesis: the transfer of cinnamoyl from cinnamoyl-CoA to harpagide.
• Novel Motif Discovery: The authors discovered a distinct VYPWG motif in the SnHS enzyme (and related Clade 6i enzymes), which differs from the canonical DFGWG motif found in most BAHD acyltransferases. This suggests a structural adaptation for specific substrate recognition.
• Model System Establishment: Established Scrophularia nodosa as a superior, sustainable model for studying iridoid metabolism and producing harpagoside, as it accumulates the compound in leaves (non-destructive harvesting) and has a manageable life cycle.

4. Key Results

• Genome Assembly: The S. nodosa genome was assembled into 18 pseudochromosomes with 99.5% BUSCO completeness. It revealed an ancient whole-genome duplication event (~30–40 Mya).
• Early Pathway Validation: Transient expression of S. nodosa early pathway genes in N. benthamiana successfully produced 8-epi-deoxyloganic acid. Interestingly, SnISY and SnICYC were found to be essential, while other steps showed some promiscuity or spontaneous conversion.
• Candidate Selection: Among 21 highly expressed Clade 6 BAHD genes, Sno.1336 showed the highest correlation (PCC = 0.84) with harpagoside content, particularly in unopened buds and young leaves.
• Enzymatic Characterization of SnHS:
  • Activity: SnHS efficiently converts harpagide + cinnamoyl-CoA $\rightarrow$ harpagoside.
  • Acceptor Specificity: Highest activity with harpagide; also active with ajugol (precursor) and loganic acid.
  • Donor Specificity: Highly specific for cinnamoyl-CoA ($K_m$ = 192 µM). It showed low activity with para-coumaroyl-CoA but significant activity with ortho-coumaroyl-CoA. It cannot use benzoyl-CoA or feruloyl-CoA effectively.
• Phylogenetic Insight: The VYPWG motif is conserved in branches 2 and 3 of Clade 6i, which are specific to Lamiales and Scrophulariaceae. Notably, Sesamum indicum (Pedaliaceae, the family of H. procumbens) lacks these specific sequences, suggesting convergent evolution of harpagoside biosynthesis in H. procumbens and S. nodosa.

5. Significance

• Sustainable Production: The elucidation of the harpagoside pathway in S. nodosa provides a blueprint for engineering sustainable production of this high-value drug in plants or microbial chassis, reducing pressure on endangered H. procumbens populations.
• Enzyme Engineering: The discovery of a BAHD enzyme with a VYPWG motif and specific cinnamoyl-CoA preference expands the understanding of BAHD evolution and substrate specificity. This enzyme can be used as a biocatalyst for producing cinnamoylated iridoids and other conjugates.
• Metabolic Engineering: With the early pathway reconstructed and the final step enzyme identified, the complete pathway for harpagoside is now accessible for metabolic engineering efforts.
• Evolutionary Biology: The study highlights how specialized metabolic pathways can evolve convergently in different plant families (Scrophulariaceae vs. Pedaliaceae) to produce the same bioactive molecule, driven by specific gene family expansions (BAHD Clade 6i).